


Chimeric Antigen Receptor T-Cell Therapy (CAR T)

CAR T-Cell Therapy is an extraordinary and innovative cancer treatment paradigm that engineers a patient's own cells to hunt and attack cancer cells. A personalized, next-generation treatment, CAR T is a new and powerful tool for treating advanced forms of cancer and bringing hope to patients and families.

How CAR T Works¹



Benefit to Patients



CAR T therapies have been **approved to treat both children and adults** with blood cancers, such as lymphoma and leukemia. This unique approach harnesses the power of the immune system to deliver treatment to patients who often had no other options.



Though patient response to each CAR T therapy may differ, a number of trials have shown positive results. **Patients in clinical trials have demonstrated overall response rates ranging from 52% to 82%.³**



Multiple studies have demonstrated that CAR T can improve patients' quality of life in addition to extending their life expectancy. Depending on clinical trial data on CAR T treatments that are being studied in earlier lines of care, the therapies could result in better health outcomes and greater cost savings than the current standard of care.³



While today's CAR T therapies may be the last, best hope for some patients with blood cancers, the future remains bright: **Clinical trials are underway in earlier lines of care.⁴**

Hope for The Future

In less than five years since the first CAR T therapy received FDA approval, CAR T has become a clinically proven, innovative option for select patients. CAR T represents hope for many cancer patients who have exhausted other treatment options, but only if it is accessible to them.



APPROVED THERAPIES

The FDA has approved CAR T-cell therapies to treat certain hematologic cancers.



INNOVATION PIPELINE

With hundreds of clinical trials underway, CAR T-cell therapies are being investigated for different types of cancers, including brain cancer, breast cancer, multiple myeloma and ovarian cancer.⁷

CAR T at BMS

In keeping with BMS' history of patient-centered innovation in oncology, research is underway into potential CAR T therapies and additional indications for the future.

BMS PIPELINE:

| Indication | Discovery & Validation | Clinical Trials | FDA Approval |
|---------------------|------------------------|-----------------|--------------|
| Multiple Myeloma | ✓ | ✓ | |
| B Cell Malignancies | ✓ | ✓ | |



Cost-Effective Treatment: CAR T is a highly specialized treatment that is tailored to each individual patient. Studies from the Journal of Clinical Oncology and the Journal of National Cancer Institute have determined that CAR T is cost-effective, addresses unmet need and offers treatments with potentially long-lasting and ongoing impact.^{5,6}

1. CAR T-Cell Process" <https://lymphoma.org/aboutlymphoma/treatments/cartcell/>
 2. "CAR T Cell Therapy," Cancer.gov <<https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy>>
 3. Huang et al. Journal of Hematology & Oncology (2020) 13:86 <https://doi.org/10.1186/s13045-020-00910-5>
 4. Xin Yu et al. Nature. (2020) 18:821 <https://www.nature.com/articles/d41573-019-00090-z>
 5. Lin et al. Journal of Clinical Oncology (2018) 36:32 <https://ascopubs.org/doi/10.1200/JCO.2018.79.0642>
 6. Leech et al. Journal of the National Cancer Institute (2019) 111:7 <https://academic.oup.com/jnci/article/111/7/644/5240702>
 7. Hartmann et al. EMBO Mol Med. (2017) 9:9 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582407/>